PRISM BioLab Corporation is pleased to announce its initial listing on the Tokyo Stock Exchange Growth Market today. We would like to take this opportunity to express our sincere gratitude to all our stakeholders for their unwavering support and cooperation. For more details regarding our new listing, please visit the Tokyo Stock Exchange website. https://www.jpx.co.jp/listing/stocks/new/index.html...
アーカイブ: ニュース
東京証券取引所グロース市場への上場承認に関するお知らせ
PRISM BioLab is pleased to announce that the Tokyo Stock Exchange today approved the initial listing of our shares on the Growth Market of the Tokyo Stock Exchange. Read Full Press Release-Japanese Text Only
PRISM BioLab、小野薬品工業 とのライセンス契約締結のお知らせ
TOKYO, Japan, 25 Apr 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. . Read Full Press Release
株式分割に関する基準日設定公告
株式分割に関する基準日設定公告(pdf)
PRISM BioLab、イーライリリー・アンド・カンパニーとsantec Holdingsから15億円の資金調達実施のお知らせ
TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of...
PRISM BioLab、米国製薬大手イーライリリー・アンド・カンパニーとライセンスおよび共同研究契約を締結
TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company. Read Full Press Release
Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein–Protein Interaction between CTLA-4 and B7-1
Pharmaceuticals 2022, 15(12), 1506
Tsuihiji, Kumiko; Honda, Eiji; Kojoh, Kanehisa; Katoh, Shizue; Taguri, Tomonori; Yoshimori, Atsushi; Takashima, Hajime
Development of low-molecular-weight compounds targeting the cancer-associated KLF5 transcription factor
ACS Medicinal Chemistry Letters, 13(4), 687-694 (2022)
Nakaya, Takeo; Aizawa, Kenichi; Taguchi, Yuki; Tsuji, Kentaro; Sekine, Sachi; Murakami, Kazuhiro; Kasai, Masaji; Nakano, Hirofumi; Kondoh, Yasumitsu; Dan, Shingo; Yoshimori, Atsushi; Kouji, Hiroyuki; Takehara, Dai; Suzuki, Toru; Osada, Hiroyuki; Marata, Masayuki; Tanaka, Akira; Nagai, Ryozo
PRISM BioLab、大原薬品工業 とライセンス契約に基づくマイルストン達成のお知らせ
TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing...
サイクリックペプチド模倣技術を用いたCTLA-4とB7-1のPPI阻害剤創出に関する論文が、PharmaceuticalsのPPI特集号に掲載されました
The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein Interactions (PPIs): Current Strategies for the Development of New Drugs” presents a new method to generate small-molecules PPI inhibitors using only a sequence of a binding peptide. Potent and active PPI inhibitor peptides can be readily generated by various...